Individual patient data-based meta- analysis assessing the interest of pre- operative chemotherapy in resectable oesophageal carcinoma Abstract: 4512 Thirion.

Slides:

Advertisements

Similar presentations

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Advertisements

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Treatment in Advanced Non-Small Cell Lung Cancer.

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.

Facon T et al. Proc ASH 2013;Abstract 2.

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

V. Budach – Statements on H&N Cancer - 1 Discussion Panel on Primary Radiochemotherapy Volker Budach, MD, PhD Head Department for Radiation Oncology Charité.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.

A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Intergroup trial CALGB 80101

Lymphadenectomy in Epithelial Ovarian Cancer

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma Nabeel Pervaiz Nigel.

HCI Sarcoma Services Sequential Dependency of Radiotherapy for Soft-Tissue Sarcoma S Sampath TE Schultheiss YJ Hitchcock RL Randall DC Shrieve JYC Wong.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Outcomes Following Adjuvant 5-FU based Treatment (AT) for Colon Cancer vs Impact on Recurrence Rate, Time from Recurrence to Death.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

Prof. Francesco Boccardo University and National Cancer Research Institute of Genoa, Italy Prof. Francesco Boccardo University and National Cancer Research.

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.

How should efficacy of new adjuvant therapies be evaluated in colorectal cancer? Marc Buyse, ScD IDDI, Brussels, Belgium Based on Daniel Sargent’s talks.

0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower.

‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.

Lymph Node (LN) Ratio (LNR) Based Risk Classification (RC) in Stage III Colon Cancer (CC) with Internal and External Validation: Finding from the ACCENT.

The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.

Therapeutic Delay and Survival after Surgery for Cancer of the Pancreatic Head with or without Preoperative Biliary Drainage Eshuis, van der Gaag, Rauws.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,

Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.

Age > 50 Abstract Background Limited data exists regarding outcomes and AT benefit/toxicity in Y pts with stage II and III CC. We examined overall survival.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.

Reducing Tobacco Intake Lowers Risk of Lung Cancer in Heavy Smokers Slideset on: Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Slamon D et al. SABCS 2009;Abstract 62.

A cura di Filippo de Marinis

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Verstovsek S et al. Proc ASH 2011;Abstract 793.

What is the optimal pre-op therapy for esophagus and GE junction cancers?

ACT II: The Second UK Phase III Anal Cancer Trial

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Presentation transcript:

Individual patient data-based meta- analysis assessing the interest of preoperative chemotherapy in resectable oesophageal carcinoma Abstract: 4512 Thirion P., Michiels S., Le Maître A., Tierney J. The Meta ‑ Analysis of Chemotherapy in Esophagus Cancer Collaborative Group

Rational & Background Improvement of survival of patients with locally advanced resectable oesophageal cancer is warranted Pre-operative strategies:  Pre-operative radiotherapy  IPD-Meta-analysis (Arnott et al., 1998)  Pre-operative chemotherapy  Literature-based Review (Cochrane, 2005)  Pre-operative Chemo-radiotherapy  Literature-based Review (Gebski et al., 2007)

Methods Objectives  Primary end-point:  OS: Overall Survival  Secondary end-point:  DFS : Disease-Free Survival, using a 6-month landmark method  RO Complete Resection rate (UICC-AJCC definition)  Post-operative mortality rate Statistical analyses  IPD updated / centrally collected, checked & re-analysed  Intention-to-treat analyses  Odds Ratio (OR), Hazard ratio (HR) & Logrank test - stratified by trial  Kaplan-Meier survival curves  Heterogeneity and interaction tests  Planned Sub-group analyses for OS and DFS:  Age, gender, initial Performance Status (PS) & histological type

Materials 12 eligible trials identified - 2,290 patients 9 available trials (10 comparisons) - 2,102 patients (92%) Median follow up across trials: 5.3 years (range: )

Population Characteristics Patient population characteristics  Age > 60 : 54%  Male: 79%  Initial PS 0-1: 71% (not available in 3 trials, 533 pts)  Squamous Cell Carcinoma: 54%  Tumour location:  Middle and lower 3 rd : 67%  GE junction: 11% Available outcome variables  OS: 9 trials - 2,102 patients  DFS: 7 trials - 1,849 patients  R0 Complete Resection rate: 7 trials - 1,887 patients  Post-operative mortality rate: 7 trials - 1,849 patients

Primary End-point: Overall Survival

HR = 0.87 [0.79;0.95], p= %20.4%16.1%5 years 5.1%37.5%32.4%2 years Absolute benefit Chemo pre-op Control Patients at risk Control Chemo pre-op Survival Time (years)

Secondary End-point: DFS

HR = 0.82 [0.74;0.91], p= %11.8%7.4%5 years 7.0%30.1%23.1%2 years Absolute benefit Chemo pre-op Control Patients at risk Control Chemo pre-op Disease free survival Time (years)

Secondary End-point: R0 Resection Rate Intention-to-treat Analysis Queen Mary48/7439/ Italy37/4835/484.5 MRC EO-02233/400215/ RTOG /233138/ MD Anderson13/1716/ Scandinavia 223/5616/ Scandinavia 2R28/5320/ Oeso-235/5840/ Total561/939519/ Study Chemo preop No. Events / No. Entered Control O-EVariance Odds ratioOR (95% CI) Chemo preop effect with p = 0.02 Test for heterogeneity: p = [ ] Chemo preop better|Control better

Secondary End-point: Post-operative Mortality Rate Queen Mary1/745/ Italy1/482/ Songkla3/240/ MRC EO-0236/40040/ RTOG 89118/2335/ Oeso-29/587/ Rotterdam4/853/ Total62/92262/ Study Chemo preop No. Events / No. Entered Control O-EVariance Odds ratioOR (95% CI) No preop Chemo effect p = 0.94 NS Test for heterogeneity: p = [ ] Chemo preop better|Control better

Sub-group Analyses The overall survival and disease-free survival benefit of the addition of pre-operative chemotherapy was seen across:  Age (50 60)  Gender  Initial PS  Histological Type Adenocarcinoma282/385315/ Squamous cell450/564471/ Category Chemo preop No. Events / No. Entered Control O-EVarHazard ratioHR [95% CI] Test for interaction:p = 0.21 Chemo preop better|Control better

Conclusions For patients with resectable oesophageal cancer, pre-operative chemotherapy:  Improves significantly Overall Survival and Disease Free Survival, regardless of age, gender, PS & histological type.  Increases R0 resection rate, without increasing post-operative mortality rate

Acknowledgments Writing/Steering Committee: Thirion P., Piedbois Y., Tierney J., Stenning S., Pignon J.P., Buyse M., Piedbois P., Bosset J.F. Secretariat: Thirion P., Michiels S., Pignon J.P., Piedbois P., Le Maître A. Collaborators (Investigators & Statisticians): Ancona E., Apinop C., Bancewicz J., Clark P., De Vathaire F., Giuli R., Hansen H.S., Kelsen D., Kok T.C., Kullathorn T., Law S., Maipang T., Nygaard K., Parmar M., Roth J., Ruol A., Steinberg S., Tierney J, Tilanus H.W., Van der Gaast A., Winter K., Wong J. Supported by French Cancer Ligue And the patients.